CliffBio
small molecule

TYVASO DPI

TREPROSTINIL

Loss of exclusivityFebruary 2042latest FDA-listed patent expiry
CompanyUnited Laboratories →See this company's full patent-cliff portfolio

Drug detail

Brand nameTYVASO DPI
Active ingredientTREPROSTINIL
Strength0.048MG/INH
Dosage formPOWDER
RouteINHALATION
ModalitySmall molecule
FDA approvalMay 2022
Marketing statusRX

Listed patents

PatentExpiresType
11826327February 2042use U-3749
10421729April 2035product
10772883June 2030product
9593066December 2028substance
11723887December 2028substance
11357782May 2027use U-1849

More from United Laboratories

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

TYVASO DPI patent cliff — loss of exclusivity February 2042 | CliffBio